non injectable glp 1 injection The Rise of the GLP-1s: Beyond Diabetes and Obesity 🚨 Big Advances in GLP-1

There is increasing concern about the development of pancreatitis in patients with diabetes mellitus who received long-term glucagon-like peptide-1 (GLP-1) analog treatment

In the past two years, Ive spent time assessing and working with and through the phenomenon of GLP-1s in health care through the consumer lens and how this category of prescription drugs are profoundly impacting many segments of the U.S

GLP-1 receptor agonists like semaglutide can slow gastric emptying, potentially reducing birth control pill absorption and effectiveness

Struggling with GLP-1 therapy side effects

However, the coexistence of micro and macrovascular disease is associated with the highest cardiovascular risks which highlights the importance that pharmacological treatment of type 2 diabetes mellitus provides not only glycemic control, but also cardiovascular safety